Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer.

Joost M Blok Harmke J GrootEline H HueleRonald de WitSimon HorenblasJanine NuverGerard Groenewegen J L H Ruud BoschJ Alfred WitjesJacqueline M TrompPeter J M de BrouwerHetty A van den BergBen G L VannesteTineke J SmildeMaureen J B AartsJourik A Gietema Richard P Meijer Michael Schaapveld

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)

Approximately one in every 30 survivors of TGCT will develop a CTGCT, with CTGCT incidence increasing up to 20 years after a primary TGCT. Treatment with platinum-based chemotherapy shows a dose-dependent inverse association with CTGCT risk.

Keyphrases

locally advanced
papillary thyroid
risk factors
young adults
radiation therapy
chemotherapy induced
childhood cancer
replacement therapy
smoking cessation